Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
CONTEXT
Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of… Expand
Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors
- S. Maeng, C. Zarate, J. Du, R. Schloesser, H. Manji
- Chemistry, Medicine
- Biological Psychiatry
- 15 February 2008
BACKGROUND
Ketamine exerts a robust, rapid, and relatively sustained antidepressant effect in patients with major depression. Understanding the mechanisms underlying the intriguing effects of… Expand
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
- P. Zanos, R. Moaddel, +17 authors T. Gould
- Medicine
- Nature
- 24 April 2016
Major depressive disorder affects around 16 per cent of the world population at some point in their lives. Despite the availability of numerous monoaminergic-based antidepressants, most patients… Expand
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.
- Nancy Diazgranados, Lobna A Ibrahim, +10 authors C. Zarate
- Psychology, Medicine
- Archives of general psychiatry
- 1 August 2010
CONTEXT
Existing therapies for bipolar depression have a considerable lag of onset of action. Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or… Expand
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
- G. Sanacora, C. Zarate, J. Krystal, H. Manji
- Medicine
- Nature Reviews Drug Discovery
- 1 May 2008
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and… Expand
Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial
- C. Zarate, N. Brutsche, Lobna A Ibrahim, José A. Franco-Chaves, D. Luckenbaugh
- Psychology, Medicine
- Biological Psychiatry
- 1 June 2012
BACKGROUND
Currently, no pharmacological treatments for bipolar depression exist that exert rapid (within hours) antidepressant or antisuicidal effects. We previously reported that intravenous… Expand
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
- Nancy Diazgranados, Lobna A Ibrahim, +5 authors C. Zarate
- Psychology, Medicine
- The Journal of clinical psychiatry
- 13 July 2010
OBJECTIVE
Suicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an… Expand
Ketamine for Depression: Where Do We Go from Here?
- M. Rot, C. Zarate, D. Charney, S. Mathew
- Medicine
- Biological Psychiatry
- 1 October 2012
Since publication of the first randomized controlled trial describing rapid antidepressant effects of ketamine, several reports have confirmed the potential utility of this dissociative anesthetic… Expand
The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence.
- M. Tohen, C. Zarate, +5 authors R. Baldessarini
- Psychology, Medicine
- The American journal of psychiatry
- 1 December 2003
OBJECTIVE
Since improved prediction of illness course early in bipolar disorder is required to guide treatment planning, the authors evaluated recovery, first recurrence, and new illness onset… Expand
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study
- M. Tohen, R. Baker, L. Altshuler, C. Zarate, L. Schuh
- Medicine
- European Neuropsychopharmacology
- 31 December 2001
OBJECTIVE
Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex.
METHOD… Expand
...
1
2
3
4
5
...